Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Announces Extraordinary General Meeting for Strategic Amendments

Tip Ranks
2025.11.04 10:07
portai
I'm PortAI, I can summarize articles.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Announces Extraordinary General Meeting for Strategic Amendments

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ) has provided an announcement.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced an extraordinary general meeting to be held on November 26, 2025, to discuss significant changes including the use of proceeds from its A share IPO and amendments to its Articles of Association. These changes could impact the company’s governance structure and operational strategies, potentially affecting its market positioning and stakeholder interests.

More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is focused on developing and manufacturing pharmaceutical products, with a market focus on innovative drug development and biotechnology solutions.

Average Trading Volume: 6,079,766

Current Market Cap: HK$1.09B

Learn more about 1349 stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.